ICON plc filings document current-report disclosures for a foreign private issuer in the clinical research organization sector. Form 6-K reports furnish press releases and exhibits on operating results, financial guidance, earnings-call scheduling, conference presentations, shareholder voting matters, governance updates, and clinical or regulatory disclosures.
The filings also record accounting-practices and internal-control matters, including revenue-recognition disclosures, as well as XBRL financial information covering operating results, equity accounts and reporting-segment data. These documents frame ICON’s public-company reporting around clinical development services, capital structure, governance and risk-related material events.
ICON plc (ICLR) reported third-quarter 2026 revenue of $2,024.8 million, down 2.9% from a year earlier, and net income of $122.1 million versus a $284.2 million loss. Income from operations was $198.8 million, compared with an operating loss of $222.9 million. For the nine months, revenue was $6,122.2 million, down 0.3%, while net income was $299.5 million versus $80.1 million. Nine-month operating cash flow was $793.4 million.
During the quarter, ICON repurchased 2,359,703 ordinary shares for $400.0 million. After the Board’s October 20, 2026 authorization, remaining repurchase capacity was up to $750.0 million as of October 27, 2026. In August, a wholly owned subsidiary issued $2.15 billion of senior unsecured notes; proceeds repaid the $900.0 million senior secured term loan, redeemed $750.0 million of May 2027 notes, and repaid $500.0 million under the bridge facility. ICON recorded a $12.2 million loss on debt extinguishment. The company also reported approximately $16.4 billion of unsatisfied performance obligations, with approximately 47% expected to be recognized over the next 12 months, subject to potential project cancellation or delay.
ICON plc reported third-quarter 2026 revenue of $2,024.8 million, down 2.9% year over year, and net business wins of $3,150 million, producing a 1.56x book-to-bill. Backlog was $24.5 billion as of September 30, 2026, up 4.8% sequentially. GAAP net income was $122.1 million, compared with a net loss of $284.2 million in third-quarter 2025. Adjusted net income was $205.8 million; adjusted diluted EPS was $2.66, compared with $3.20 in third-quarter 2025. Adjusted EBITDA was $336.9 million, or 16.6% of revenue, down 13.1% year over year.
Free cash flow was $302.4 million, and ICON repurchased $400.0 million of stock at an average price of $170 per share; the board increased the total authorized share repurchase value to $750.0 million. In August 2026, ICON completed an investment grade bond issuance of $2.15 billion and applied net proceeds to repay the $900 million Senior Secured Term Loan, redeem the $750 million May 2027 Notes, and repay $500 million outstanding under the Bridge Secured Credit Facility. ICON expects full-year 2026 revenue of $8,100–$8,200 million and adjusted diluted EPS of $10.35–$10.65.
ICON plc's Chief Accounting Officer, Emer Lyons, had 510 restricted share units vest in full in one installment on October 22, 2026, settling into 510 ordinary shares. Each unit represented a contingent right to receive one ordinary share; a nominal conversion price of EUR 0.06 per underlying share was automatically deducted from pay in connection with vesting. On October 23, 2026, Lyons sold 272 ordinary shares in a sell-to-cover transaction to satisfy tax withholding obligations; the sale was described as non-discretionary. The five reported weighted-average prices ranged from $180.5400 to $184.2900 per share. No Rule 10b5-1 plan is reported.
ICON plc (ICLR) said it will release its third-quarter 2026 financial results after the market closes on October 27, 2026. The company scheduled a conference call and webcast to discuss the results and performance for October 28, 2026, at 8:00 a.m. ET. ICON said it will post event changes and available live webcast links in the Investor section of its website.
ICON PLC (ICLR) director Dr. John Climax reported an option exercise and same‑day share sale. On September 16, 2026 he exercised fully vested stock options to acquire 5,005 Ordinary Shares at an exercise price of $125.74 per share, then sold 5,005 Ordinary Shares at $175.00 per share. The exercised option grant, originally dated May 18, 2018, is now fully exhausted, and no remaining derivative position from this grant is reported. No Rule 10b5‑1 trading plan is indicated.
ICON PLC (ICLR) director Eugene Pacelli McCague exercised stock options for 3,255 Ordinary Shares on September 17, 2026 at an exercise price of $125.74 per share and sold the same 3,255 shares at $175.00 per share the same day. The underlying options were fully vested and, after the exercise, 0 options from this grant remained outstanding.
The company notes that as a foreign private issuer, these equity transactions are exempt from Sections 16(b) and 16(c) of the Securities Exchange Act of 1934.
ICON PLC (ICLR) director Ronan Martin Murphy reported an option exercise and sale on September 17, 2026. He exercised 5,005 stock options into 5,005 Ordinary Shares at an exercise price of $125.74 per share, then sold the same 5,005 shares at $175.00 per share in a market transaction. The options were fully vested and carry an original expiration tied to their May 18, 2018 grant date, subject to automatic extension under the company’s Share Trading Policy and applicable law.
ICON PLC (ICLR) has a notice from director Eugene Pacelli McCague indicating an intent under Rule 144 to sell up to 3,255 shares of common stock. The planned sale, dated September 17, 2026, is in connection with an exercise of options under a registered plan and will be executed through Morgan Stanley Smith Barney LLC. The notice also reports a prior sale of 841 shares on August 11, 2026.
ICON PLC (ICLR) has a notice of proposed resale of shares under Rule 144 filed on behalf of director Ronan Martin Murphy. The filing indicates an intended sale of 5,005 shares of common stock, with an aggregate value shown as $875,875.00, through Morgan Stanley Smith Barney LLC, with the securities noted as listed on NASDAQ.
The shares to be sold on September 17, 2026 are described as arising from the exercise of options under a registered plan, with settlement by wire. The filing also reports that in the prior three months, Murphy sold 841 shares of common stock on August 11, 2026 for an aggregate amount of $138,169.82.
ICON PLC (ICLR) director John Climax filed a Form 144 indicating a proposed sale of 5,005 common shares of ICON for an aggregate value of $875,875.00 through Morgan Stanley Smith Barney LLC on September 16, 2026. The shares are to be sold following the exercise of options under a registered plan. The filing also notes a prior sale of 841 shares of common stock on August 11, 2026 for $138,169.82.